History
- December 2004: Napa Jenomics Corporation established in California, USA
- July 2005: Napa Jenonics K.K. established in Tokyo, Japan as a subsidiary of Napa Jenomics Corporation
- February 2009 Company started to focus nucleic acid drug discovery and development effort
- July 2011: Napa Jenomics Corporation changes name to NapaJen Pharma, Inc,
- January 2014: Closed Series A financing
- December 2016: Closed Series B financing
- January 2017: Advanced NJA-730 into development stage
- January 2018: Napa Jenomics Co., Ltd. changes name to NapaJen Pharma Co., Ltd.
- September 2018: Phase 1 clinical trial of NJA-730 launched in Australia
- January 2019: Closed Series C financing